Jamie Miller to Anti-Bacterial Agents
This is a "connection" page, showing publications Jamie Miller has written about Anti-Bacterial Agents.
Connection Strength
1.518
-
Impact of Ceftazidime Use on Susceptibility Patterns in the Neonatal Intensive Care Unit. Pediatr Infect Dis J. 2019 06; 38(6):605-607.
Score: 0.456
-
Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017 Dec; 18(12):e615-e620.
Score: 0.411
-
Impact of Ceftazidime Use on Susceptibility Patterns in a Neonatal Intensive Care Unit: A 7.5-year Evaluation. J Pediatric Infect Dis Soc. 2022 07 21; 11(7):349-350.
Score: 0.142
-
Evaluation of Ceftazidime Use in the Neonatal Intensive Care Unit and Association With Cephalosporin-Resistant Gram-Negative Bacteria. Ann Pharmacother. 2022 Dec; 56(12):1325-1332.
Score: 0.139
-
Hyponatremia With Intravenous Sulfamethoxazole/Trimethoprim in Children. Ann Pharmacother. 2020 04; 54(4):351-358.
Score: 0.117
-
Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. J Oncol Pharm Pract. 2019 Apr; 25(3):520-528.
Score: 0.102
-
"Once-daily" versus "extended-interval" administration of aminoglycosides in neonates: need for standard terminology. Am J Health Syst Pharm. 2014 Dec 15; 71(24):2108-9.
Score: 0.084
-
Vancomycin dosage in overweight and obese children. Am J Health Syst Pharm. 2011 Nov 01; 68(21):2062-8.
Score: 0.067